• Cadrenal Therapeutics priced a private placement issuing 960,000 shares or pre-funded warrants, with series C-1 and C-2 warrants for 960,000 shares each.
• Combined purchase price set at USD 3.13 per share with accompanying warrants; upfront gross proceeds expected at USD 3 million.
• Both warrant series carry a USD 3 exercise price; C-2 warrants exercisable immediately, C-1 warrants require stockholder approval.
• Full cash exercise could add about USD 5.8 million; a resale registration statement will be filed covering the securities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-074421), on July 01, 2026, and is solely responsible for the information contained therein.